Melissa J. Kasiewicz

Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity

William L. Redmond, Stefanie N. Linch, Melissa J. Kasiewicz · Cancer Immunology Research · 2013 · 166 citations · Full text

Life Sciences, Immunology, Oncology +17

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice

Stefanie N. Linch, Melissa J. Kasiewicz, Michael J. McNamara et al. · Proceedings of the National Academy of Sciences · 2016 · 76 citations · Full text

Life Sciences, Immunology, Oncology +17

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity

Elizabeth R. Sturgill, Annah S. Rolig, Stefanie N. Linch et al. · OncoImmunology · 2021 · 51 citations · Full text

Life Sciences, Immunology, Oncology +17

The Peripheral Myeloid Expansion Driven by Murine Cancer Progression Is Reversed by Radiation Therapy of the Tumor

Marka R. Crittenden, Talicia Savage, Benjamin Cottam et al. · PLoS ONE · 2013 · 44 citations · Full text

Medicine, Immunology, Oncology +17

Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth

Mark Badeaux, Annah S. Rolig, Giulia Agnello et al. · Cancer Immunology Research · 2021 · 43 citations · Full text

Life Sciences, Immunology, Oncology +17